- Cat. No.
- ABS 012-35
- Product name
- Anti-Exendin-4
- Description
-
Mouse monoclonal antibody
- Specificity
Specific for exendin-4. No cross-reactivity with GLP-1, GLP-2 (human) or glucagon coated on ELISA wells.
- Immunogen
Synthetic exendin-4
- Application
- ELISA
- Species reactivity (positive)
- Human
- Species reactivity (negative)
- Not determined
- Subclass
IgG1/k
- Gene ID
- 2740
- Clone number
- 35
- Epitope
The epitope is in the 9-39 region of the peptide, and the antibody cross-reacts strongly with exendin (9-39)amide.
- Content
Available in 200 µL and 1 mL size.1 mg/mL +/- 15%. See Certificate of Analysis for details.
- Purification
- Protein-A purified
- Form
- Liquid
- Solvent
- 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
- Storage
- 4-8ºC without exposure to light. No precautions necessary during handling.
- Target
Exendin-4 is a 39 amino acid peptide found in venom from the Gila monster
Heloderma suspectum. It is a member of the glucagon-secretin family of peptide hormones and neuropeptides. Exendin-4 is a potent agonist of the GLP-1 receptor and hence a potent stimulator of insulin secretion.
- Application 1
- ELISAABS 012-35 binds to exendin-4 when coated on ELISA wells and reacts specifically with exendin-4 in solution giving a Ka of 1.1x10E9 in an inhibition ELISA. The binding between ABS 012-35 and exendin-4 is disrupted by 4.5 M MgCl2.ABS 012-35 (as biotinylated detection antibody) forms a sandwich ELISA pair with ABS 033-10 (as capture antibody) for measuring exendin-4, giving a detection limit of as little as 40 pmol/L in an unoptimized buffer assay (1).
By using the above monoclonal antibodies, it is possible to measure intact exendin-4 by a sandwich ELISA which is not subject to interference from GLP-1 or other glucagon-related peptides that may be present. ABS 033-10 is used as capture antibody in combination with a biotinylated detection antibody from the ABS 012 series. The best sensitivity in an unoptimized buffer assay was obtained with biotinylated ABS 012-35 as the detection antibody.
1. Murphy RE, Kinhikar AG, Shields MJ, Rosario JD, Preston R, Levin N, Ward GH (2010) Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. Journal of Pharmaceutical and Biomedical Analysis 53:221-227.
- 20547023
